561 related articles for article (PubMed ID: 31642874)
1. Apolipoprotein B Particles and Cardiovascular Disease: A Narrative Review.
Sniderman AD; Thanassoulis G; Glavinovic T; Navar AM; Pencina M; Catapano A; Ference BA
JAMA Cardiol; 2019 Dec; 4(12):1287-1295. PubMed ID: 31642874
[TBL] [Abstract][Full Text] [Related]
2. Physiological Bases for the Superiority of Apolipoprotein B Over Low-Density Lipoprotein Cholesterol and Non-High-Density Lipoprotein Cholesterol as a Marker of Cardiovascular Risk.
Glavinovic T; Thanassoulis G; de Graaf J; Couture P; Hegele RA; Sniderman AD
J Am Heart Assoc; 2022 Oct; 11(20):e025858. PubMed ID: 36216435
[TBL] [Abstract][Full Text] [Related]
3. Apolipoprotein B compared with low-density lipoprotein cholesterol in the atherosclerotic cardiovascular diseases risk assessment.
Galimberti F; Casula M; Olmastroni E
Pharmacol Res; 2023 Sep; 195():106873. PubMed ID: 37517561
[TBL] [Abstract][Full Text] [Related]
4. Relation between low-density lipoprotein cholesterol/apolipoprotein B ratio and triglyceride-rich lipoproteins in patients with coronary artery disease and type 2 diabetes mellitus: a cross-sectional study.
Tani S; Yagi T; Atsumi W; Kawauchi K; Matsuo R; Hirayama A
Cardiovasc Diabetol; 2017 Oct; 16(1):123. PubMed ID: 28969633
[TBL] [Abstract][Full Text] [Related]
5. Diagnosis and treatment of apolipoprotein B dyslipoproteinemias.
Sniderman A; Couture P; de Graaf J
Nat Rev Endocrinol; 2010 Jun; 6(6):335-46. PubMed ID: 20421882
[TBL] [Abstract][Full Text] [Related]
6. Cholesterol not particle concentration mediates the atherogenic risk conferred by apolipoprotein B particles: a Mendelian randomization analysis.
Helgadottir A; Thorleifsson G; Snaebjarnarson A; Stefansdottir L; Sveinbjornsson G; Tragante V; Björnsson E; Steinthorsdottir V; Gretarsdottir S; Helgason H; Saemundsdottir J; Olafsson I; Thune JJ; Raja AA; Ghouse J; Olesen MS; Christensen A; Jacobsen RL; Dowsett J; Bruun MT; Nielsen K; Knowlton K; Nadauld L; Benediktsson R; Erikstrup C; Pedersen OB; Banasik K; Brunak S; ; Bundgaard H; Ostrowski SR; Sulem P; Arnar DO; Thorgeirsson G; Thorsteinsdottir U; Gudbjartsson DF; Stefansson K; Holm H
Eur J Prev Cardiol; 2022 Dec; 29(18):2374-2385. PubMed ID: 36125206
[TBL] [Abstract][Full Text] [Related]
7. Preferential reduction of very low density lipoprotein-1 particle number by fenofibrate in type IIB hyperlipidemia: consequences for lipid accumulation in human monocyte-derived macrophages.
Milosavljevic D; Griglio S; Le Naour G; Chapman MJ
Atherosclerosis; 2001 Mar; 155(1):251-60. PubMed ID: 11223449
[TBL] [Abstract][Full Text] [Related]
8. Apolipoprotein B: the Rosetta Stone of lipidology.
Glavinovic T; Sniderman AD
Curr Opin Endocrinol Diabetes Obes; 2021 Apr; 28(2):90-96. PubMed ID: 33229928
[TBL] [Abstract][Full Text] [Related]
9. Why is non-high-density lipoprotein cholesterol a better marker of the risk of vascular disease than low-density lipoprotein cholesterol?
Sniderman A; McQueen M; Contois J; Williams K; Furberg CD
J Clin Lipidol; 2010; 4(3):152-5. PubMed ID: 21122647
[TBL] [Abstract][Full Text] [Related]
10. Non-HDL-cholesterol and apolipoprotein B compared with LDL-cholesterol in atherosclerotic cardiovascular disease risk assessment.
Carr SS; Hooper AJ; Sullivan DR; Burnett JR
Pathology; 2019 Feb; 51(2):148-154. PubMed ID: 30595507
[TBL] [Abstract][Full Text] [Related]
11. Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial.
Thomas GS; Cromwell WC; Ali S; Chin W; Flaim JD; Davidson M
J Am Coll Cardiol; 2013 Dec; 62(23):2178-84. PubMed ID: 24013058
[TBL] [Abstract][Full Text] [Related]
12. Influence of mild to moderately elevated triglycerides on low density lipoprotein subfraction concentration and composition in healthy men with low high density lipoprotein cholesterol levels.
Halle M; Berg A; Baumstark MW; König D; Huonker M; Keul Joseph
Atherosclerosis; 1999 Mar; 143(1):185-92. PubMed ID: 10208494
[TBL] [Abstract][Full Text] [Related]
13. Diurnal and acute patterns of postprandial apolipoprotein B-48 in VLDL, IDL, and LDL from normolipidemic humans.
Campos H; Khoo C; Sacks FM
Atherosclerosis; 2005 Aug; 181(2):345-51. PubMed ID: 16039289
[TBL] [Abstract][Full Text] [Related]
14. The contribution of ApoB and ApoA1 measurements to cardiovascular risk assessment.
Andrikoula M; McDowell IF
Diabetes Obes Metab; 2008 Apr; 10(4):271-8. PubMed ID: 18333887
[TBL] [Abstract][Full Text] [Related]
15. Triglyceride-rich lipoprotein cholesterol and cardiovascular risk.
Bilgic S; Remaley AT; Sniderman AD
Curr Opin Lipidol; 2023 Dec; 34(6):259-266. PubMed ID: 37773930
[TBL] [Abstract][Full Text] [Related]
16. Decrease in plasma low-density lipoprotein cholesterol, apolipoprotein B, cholesteryl ester transfer protein, and oxidized low-density lipoprotein by plant stanol ester-containing spread: a randomized, placebo-controlled trial.
Homma Y; Ikeda I; Ishikawa T; Tateno M; Sugano M; Nakamura H
Nutrition; 2003 Apr; 19(4):369-74. PubMed ID: 12679174
[TBL] [Abstract][Full Text] [Related]
17. Atherogenic Lipoprotein Determinants of Cardiovascular Disease and Residual Risk Among Individuals With Low Low-Density Lipoprotein Cholesterol.
Lawler PR; Akinkuolie AO; Chu AY; Shah SH; Kraus WE; Craig D; Padmanabhan L; Glynn RJ; Ridker PM; Chasman DI; Mora S
J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28733430
[TBL] [Abstract][Full Text] [Related]
18. Discordance between lipoprotein particle number and cholesterol content: an update.
Cantey EP; Wilkins JT
Curr Opin Endocrinol Diabetes Obes; 2018 Apr; 25(2):130-136. PubMed ID: 29324459
[TBL] [Abstract][Full Text] [Related]
19. Update on the detection and treatment of atherogenic low-density lipoproteins.
Sniderman A; Kwiterovich PO
Curr Opin Endocrinol Diabetes Obes; 2013 Apr; 20(2):140-7. PubMed ID: 23422241
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological modulation of cholesteryl ester transfer protein, a new therapeutic target in atherogenic dyslipidemia.
Le Goff W; Guerin M; Chapman MJ
Pharmacol Ther; 2004 Jan; 101(1):17-38. PubMed ID: 14729390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
